ALX Oncology Holdings Inc. – NASDAQ:ALXO
ALX Oncology Holdings stock price today
$0.867
-0.75
-46.51%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 13 hours
ALX Oncology Holdings stock price monthly change
-77.05%
month
ALX Oncology Holdings stock price quarterly change
-77.05%
quarter
ALX Oncology Holdings stock price yearly change
-89.11%
year
ALX Oncology Holdings key metrics
Market Cap | 91.50M |
Enterprise value | N/A |
P/E | -1.5 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.71 |
PEG ratio | 0.03 |
EPS | -3.71 |
Revenue | N/A |
EBITDA | -172.21M |
Income | -166.20M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeALX Oncology Holdings stock price history
ALX Oncology Holdings stock forecast
ALX Oncology Holdings financial statements
| Jun 2023 | 0 | -34.15M | |
|---|---|---|---|
| Sep 2023 | 0 | -50.99M | |
| Dec 2023 | 2.48M | -45.47M | -1833.55% |
| Mar 2024 | 0 | -35.58M |
| Mar 2024 | 0 | -35.58M | |
|---|---|---|---|
| Sep 2025 | 0 | -29.39M | |
| Oct 2025 | 0 | -36.83M | |
| Dec 2025 | 0 | -37.08M |
Analysts Price target
Financials & Ratios estimates
| 2024-03-07 | -0.84 | -0.93 |
|---|
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | 0% |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 245932000 | 33.24M | 13.52% |
|---|---|---|---|
| Sep 2023 | 220107000 | 51.35M | 23.33% |
| Dec 2023 | 242553000 | 52.84M | 21.79% |
| Mar 2024 | 212650000 | 48.45M | 22.79% |
| Jun 2023 | -31.71M | 6.21M | 343K |
|---|---|---|---|
| Sep 2023 | -31.15M | 12.81M | -111K |
| Dec 2023 | -39.67M | -16.66M | 59.16M |
| Mar 2024 | -37.92M | 26.47M | 3.08M |
ALX Oncology Holdings alternative data
| Aug 2023 | 65 |
|---|---|
| Sep 2023 | 72 |
| Oct 2023 | 72 |
| Nov 2023 | 72 |
| Dec 2023 | 71 |
| Jan 2024 | 71 |
| Feb 2024 | 71 |
| Mar 2024 | 72 |
| Apr 2024 | 72 |
| May 2024 | 72 |
| Jun 2024 | 74 |
| Jul 2024 | 74 |
ALX Oncology Holdings other data
35.55%
-53.83%
of ALXO is owned by hedge funds
48
-37
14.46M
-21.95M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 2717 |
| Mar 2024 | 4400 | 0 |
| Apr 2024 | 0 | 70000 |
| May 2024 | 0 | 32000 |
| Jun 2024 | 12000 | 20000 |
| Jul 2024 | 0 | 37227 |
| Aug 2024 | 0 | 3866 |
| Dec 2024 | 30000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | HEMRAJANI REKHA director | Common Stock | 30,000 | $1.55 | $46,410 | ||
Sale | PINTO SHELLY officer: SVP, FINANCE AND CAO | Common Stock | 564 | $2.58 | $1,455 | ||
Sale | RANDOLPH SOPHIA officer: CHIEF ME.. | Common Stock | 1,365 | $2.58 | $3,522 | ||
Sale | PONS JAUME officer: PRESIDEN.. | Common Stock | 1,937 | $2.58 | $4,997 | ||
Option | PONS JAUME director, officer.. | Common Stock | 20,000 | $0.99 | $19,800 | ||
Sale | PONS JAUME director, officer.. | Common Stock | 20,000 | $7.9 | $158,080 | ||
Option | PONS JAUME director, officer.. | Employee Stock Option (right to buy) | 20,000 | $0.99 | $19,800 | ||
Sale | PINTO SHELLY officer: SVP, FINANCE AND CAO | Common Stock | 1,823 | $5.5 | $10,025 | ||
Sale | PINTO SHELLY officer: SVP, FINANCE AND CAO | Common Stock | 1,373 | $5.82 | $7,989 | ||
Sale | RANDOLPH SOPHIA director, officer.. | Common Stock | 3,273 | $5.82 | $19,046 |
ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept
ALX Oncology Is Turning Into An Also-Ran In Anti-CD47
ALX Oncology Stock: Attractive After Recent Data And Slump In Price
ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space
-
What's the price of ALX Oncology Holdings stock today?
One share of ALX Oncology Holdings stock can currently be purchased for approximately $0.87.
-
When is ALX Oncology Holdings's next earnings date?
Unfortunately, ALX Oncology Holdings's (ALXO) next earnings date is currently unknown.
-
Does ALX Oncology Holdings pay dividends?
No, ALX Oncology Holdings does not pay dividends.
-
How much money does ALX Oncology Holdings make?
ALX Oncology Holdings has a market capitalization of 91.50M. ALX Oncology Holdings made a loss 160.81M US dollars in net income (profit) last year or -$0.93 on an earnings per share basis.
-
What is ALX Oncology Holdings's stock symbol?
ALX Oncology Holdings Inc. is traded on the NASDAQ under the ticker symbol "ALXO".
-
What is ALX Oncology Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ALX Oncology Holdings?
Shares of ALX Oncology Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ALX Oncology Holdings's key executives?
ALX Oncology Holdings's management team includes the following people:
- Dr. Jaume Pons Ph.D. Pres, Chief Executive Officer & Director(age: 59, pay: $1,280,000)
- Dr. Sophia Randolph M.D., Ph.D. Chief Medical Officer & Director(age: 57, pay: $938,500)
- Mr. Peter S. Garcia Chief Financial Officer(age: 63, pay: $817,650)
- Dr. Corey S. Goodman Ph.D. Independent Executive Chairman(age: 74, pay: $38,500)
-
How many employees does ALX Oncology Holdings have?
As Jul 2024, ALX Oncology Holdings employs 74 workers, which is 3% more then previous quarter.
-
When ALX Oncology Holdings went public?
ALX Oncology Holdings Inc. is publicly traded company for more then 5 years since IPO on 17 Jul 2020.
-
What is ALX Oncology Holdings's official website?
The official website for ALX Oncology Holdings is alxoncology.com.
-
Where are ALX Oncology Holdings's headquarters?
ALX Oncology Holdings is headquartered at 323 Allerton Avenue, South San Francisco, CA.
-
How can i contact ALX Oncology Holdings?
ALX Oncology Holdings's mailing address is 323 Allerton Avenue, South San Francisco, CA and company can be reached via phone at +65 04667125.
ALX Oncology Holdings company profile:
ALX Oncology Holdings Inc.
alxoncology.comExchange:
NASDAQ
Full time employees:
89
Industry:
Biotechnology
Sector:
Healthcare
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
323 Allerton Avenue
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001810182
ISIN: US00166B1052
CUSIP: 00166B105
